Drug Profile

Natural killer cell engager immunotherapeutic - Merck

Alternative Names: Second TriNKET™ immunotherapy candidate

Latest Information Update: 01 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dragonfly Therapeutics
Developer Merck & Co
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Solid tumours

Most Recent Events

25 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
23 Nov 2021 Second NK cell engager immunotherapeutic licensed to Merck
23 Nov 2021 Early research in Solid tumours in USA (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com